Prompt anti-VEGF dosing gave an early vision edge in retinal vein occlusion

Design

Randomised comparison of two conbercept dosing schedules (not placebo-controlled)

Population

255 patients with macular oedema from branch retinal vein occlusion

Primary outcome

Change in best-corrected visual acuity letter score at 6 months

Effect

6-month gain 16.9 vs 8.9 letters (p<0.0001); 12-month 17.1 vs 14.1 (p=0.0252)

This trial in 255 patients with macular oedema from branch retinal vein occlusion compared two conbercept dosing schedules: one group started pro-re-nata conbercept from month six, the other received an injection and then pro-re-nata dosing from the start. Both arms received the drug, so this is a comparison of timing, not drug versus placebo.

The group dosed promptly gained more vision early — a least-squares mean of 16.9 versus 8.9 letters at six months — but by twelve months the gap had narrowed (17.1 vs 14.1 letters) as the later-dosed group caught up. Central retinal thickness followed a similar pattern, and ocular and systemic safety events were low.

The lesson is familiar but worth reinforcing: in vein-occlusion macular oedema, earlier anti-VEGF treatment buys earlier visual recovery, and delay costs letters even if some are regained later. Conbercept itself is used mainly in China; where it is unavailable, the timing principle applies to the anti-VEGF agents in local use.

• Prompt pro-re-nata conbercept gave greater early vision gain (16.9 vs 8.9 letters at 6 months).
• By 12 months the difference narrowed (17.1 vs 14.1 letters) as the later-dosed group improved.
• Ocular and systemic safety events were low in both arms.
• Treat vein-occlusion macular oedema promptly; the timing principle applies whichever anti-VEGF agent is available.

Why it matters

It quantifies the cost of delay in vein-occlusion oedema, reinforcing prompt treatment.

Don't overread it

Both arms received conbercept, so this is not a placebo-controlled efficacy trial, and conbercept availability is largely limited to China.

The statistics, in plain English

A letter-score change is lines of vision on a reading chart; an 8-letter early gap is clinically meaningful. That it narrowed by a year shows the later group recovered once treated, which is why this reads as a timing lesson rather than a drug-superiority claim.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.